156. Rett syndrome Clinical trials / Disease details
Clinical trials : 44 / Drugs : 61 - (DrugBank : 23) / Drug target genes : 57 - Drug target pathways : 83
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04304482 (ClinicalTrials.gov) | July 1, 2020 | 8/3/2020 | ANAVEX2-73 Study in Pediatric Patients With Rett Syndrome | ANAVEX2-73-RS-003 is a Phase 2/3, Double-blind, Randomized, Placebo-controlled Safety and Efficacy Study in Pediatric Patients With RTT | Rett Syndrome | Drug: ANAVEX2-73 oral liquid;Drug: Placebo oral liquid | Anavex Life Sciences Corp. | Anavex Australia Pty Ltd.;Anavex Germany GmbH | Active, not recruiting | 5 Years | 17 Years | Female | 92 | Phase 2/Phase 3 | Australia;Canada;United Kingdom |
| 2 | EUCTR2019-004345-32-GB (EUCTR) | 26/05/2020 | 07/02/2020 | The use of ANAVEX2-73 as a new therapeutic treatment for Patients with Rett Syndrome | A Double-Blind, Randomised, Placebo-Controlled, Safety and Efficacy Study of ANAVEX2-73 in Patients with Rett Syndrome - The Safety and Efficacy of ANAVEX2-73 in Patients with Rett Syndrome | Rett Syndrome MedDRA version: 20.0;Level: PT;Classification code 10077709;Term: Rett syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: ANAVEX2-73 INN or Proposed INN: ANAVEX2-73 (blarcamesine) Other descriptive name: ANA001XHCl (Syntagon) or VEXA-04 (Patheon) | Anavex Germany GmbH | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: no | 30 | Phase 2 | Australia;United Kingdom | ||
| 3 | NCT03941444 (ClinicalTrials.gov) | May 6, 2019 | 6/5/2019 | ANAVEX2-73 Study in Patients With Rett Syndrome | A Double-Blind, Randomized, Placebo-Controlled, Safety and Efficacy Study of ANAVEX2-73 in Patients With Rett Syndrome | Rett Syndrome | Drug: ANAVEX2-73;Drug: Placebo | Anavex Life Sciences Corp. | NULL | Completed | 18 Years | 45 Years | Female | 33 | Phase 3 | Australia;United Kingdom |
| 4 | NCT03758924 (ClinicalTrials.gov) | February 28, 2019 | 25/11/2018 | Study of ANAVEX2-73 in Patients With Rett Syndrome | A Double-Blind, Randomized, Placebo-Controlled, Dose Titration Study of ANAVEX2-73 in Patients With Rett Syndrome | Rett Syndrome | Drug: ANAVEX2-73;Drug: Placebo | Anavex Life Sciences Corp. | International Rett Syndrome Foundation Rettsyndrome.org | Completed | 18 Years | 45 Years | Female | 31 | Phase 2 | United States |